LYEL earnings date and last-quarter result: last quarter miss, P/E -0.76. Updated 2026-07-23.
Lyell Immunopharma (LYEL) Research Hub
Lyell Immunopharma (LYEL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 9.31 USD (-0.85%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.76, market cap 0.31B. This hub links to the full technical, earnings and options research available for LYEL.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 9.31 USD (-0.85%) |
| 52-week range | 7.325 USD – 17.15 USD |
| Trend regime | Range |
| 14-day RSI | 58.1 (Bullish) |
| Trailing P/E | -0.76 |
| Market cap | 0.31B |
| Dividend yield | 0.00% |
Available research for LYEL
Covered Call on LYEL: how it works, illustrative setup around the real 9.31 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LYEL: how it works, illustrative setup around the real 9.31 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LYEL: how it works, illustrative setup around the real 9.31 USD price, max profit/loss, breakeven and when to use it. Educational.
LYEL technical analysis: range, last 9.31 USD, RSI 58.1, 52w range 7.325 USD–17.15 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is LYEL in?
Lyell Immunopharma (LYEL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is LYEL in an uptrend or downtrend?
As of 2026-10-26, LYEL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LYEL's trailing P/E ratio?
LYEL's trailing P/E is -0.76, with a market cap of 0.31B. See the earnings research page for full valuation detail.